A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Malignant Solid Neoplasm|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Pancreatic Adenocarcinoma|Metastatic Triple-Negative Breast Carcinoma|Pancreatic Ductal Adenocarcinoma|Stage III Breast Cancer AJCC v7|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage III Lung Small Cell Carcinoma AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Small Cell Carcinoma AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Small Cell Carcinoma AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Small Cell Carcinoma AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Triple-Negative Breast Carcinoma|Unresectable Lung Small Cell Carcinoma|Unresectable Pancreatic Adenocarcinoma|Unresectable Pancreatic Carcinoma|Unresectable Triple-Negative Breast Carcinoma
Interventions: OTHER: 18F-Fluoromisonidazole|DRUG: Cediranib Maleate|OTHER: Laboratory Biomarker Analysis|DRUG: Olaparib|PROCEDURE: Positron Emission Tomography
Sponsor: National Cancer Institute (NCI)
Collaborators: AstraZeneca